Cover Image
市場調查報告書

Ablynx NV- 產品平台檢討

Ablynx NV - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251639
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
Ablynx NV- 產品平台檢討 Ablynx NV - Product Pipeline Review - 2016
出版日期: 2016年05月31日 內容資訊: 英文 57 Pages
簡介

Ablynx NV是總公司位於比利時的生物製藥企業。致力於藥物研發及開發癌症、發炎、血液疾病、肺部疾病等各種領域疾病的奈米抗體。是奈米抗體的新類抗體,擁有單一可變網域,兼有傳統的抗體和低分子治療藥特徵。

本報告提供Ablynx NV的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Ablynx NV的基本資料

  • Ablynx NV概要
  • 主要資訊
  • 企業資料

Ablynx NV:R&D概要

  • 主要的治療範圍

Ablynx NV:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Ablynx NV:開發中產品概況

  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Ablynx NV:藥物簡介

  • ALX-0061
  • ALX-0171
  • caplacizumab
  • ozoralizumab
  • ALX-0141
  • Monoclonal Antibody to Target c-Met for Multiple Myeloma
  • TLC-520
  • Monoclonal Antibodies for Inflammation, Immunology and Infections
  • Monoclonal Antibodies for Oncology, Immunology and Neurology
  • Monoclonal Antibody 1 for Inflammation and Immunology
  • Monoclonal Antibody 1 for Oncology
  • Monoclonal Antibody 1 for Pulmonary Disease
  • Monoclonal Antibody 2 for Inflammation and Immunology
  • Monoclonal Antibody 2 for Oncology
  • Monoclonal Antibody 2 for Pulmonary Disease
  • Monoclonal Antibody 3 for Inflammation and Immunology
  • Monoclonal Antibody for Immunology
  • Monoclonal Antibody for Ocular Diseases
  • Monoclonal Antibody for Pulmonary Diseases

Ablynx NV:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Ablynx NV:最新的開發平台資訊

Ablynx NV:開發暫停中的計劃

Ablynx NV:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • ALX-0962
    • BI-1034020
    • Ablynx NV - Company Statement
    • Ablynx NV - Locations And Subsidiaries

Ablynx NV:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08057CDB

Summary

Global Markets Direct's, 'Ablynx NV - Product Pipeline Review - 2016', provides an overview of the Ablynx NV's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ablynx NV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Ablynx NV
  • The report provides overview of Ablynx NV including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Ablynx NV's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Ablynx NV's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Ablynx NV's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ablynx NV
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ablynx NV's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ablynx NV Snapshot
    • Ablynx NV Overview
    • Key Information
    • Key Facts
  • Ablynx NV - Research and Development Overview
    • Key Therapeutic Areas
  • Ablynx NV - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Ablynx NV - Pipeline Products Glance
    • Ablynx NV - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Ablynx NV - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Ablynx NV - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Ablynx NV - Drug Profiles
    • caplacizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALX-0061
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ozoralizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALX-0171
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALX-0141
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Immunology and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Inflammation and Osteoarthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target c-Met for Multiple Myeloma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TLC-520
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Agonize GITR for Immunology and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ablynx NV - Pipeline Analysis
    • Ablynx NV - Pipeline Products by Target
    • Ablynx NV - Pipeline Products by Route of Administration
    • Ablynx NV - Pipeline Products by Molecule Type
    • Ablynx NV - Pipeline Products by Mechanism of Action
  • Ablynx NV - Recent Pipeline Updates
  • Ablynx NV - Dormant Projects
  • Ablynx NV - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • BI-1034020
  • Ablynx NV - Company Statement
  • Ablynx NV - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ablynx NV, Key Information
  • Ablynx NV, Key Facts
  • Ablynx NV - Pipeline by Indication, 2016
  • Ablynx NV - Pipeline by Stage of Development, 2016
  • Ablynx NV - Monotherapy Products in Pipeline, 2016
  • Ablynx NV - Partnered Products in Pipeline, 2016
  • Ablynx NV - Partnered Products/ Combination Treatment Modalities, 2016
  • Ablynx NV - Out-Licensed Products in Pipeline, 2016
  • Ablynx NV - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Ablynx NV - Phase III, 2016
  • Ablynx NV - Phase II, 2016
  • Ablynx NV - Phase I, 2016
  • Ablynx NV - Preclinical, 2016
  • Ablynx NV - Discovery, 2016
  • Ablynx NV - Pipeline by Target, 2016
  • Ablynx NV - Pipeline by Route of Administration, 2016
  • Ablynx NV - Pipeline by Molecule Type, 2016
  • Ablynx NV - Pipeline Products by Mechanism of Action, 2016
  • Ablynx NV - Recent Pipeline Updates, 2016
  • Ablynx NV - Dormant Developmental Projects,2016
  • Ablynx NV - Discontinued Pipeline Products, 2016
  • Ablynx NV, Subsidiaries

List of Figures

  • Ablynx NV - Pipeline by Top 10 Indication, 2016
  • Ablynx NV - Pipeline by Stage of Development, 2016
  • Ablynx NV - Monotherapy Products in Pipeline, 2016
  • Ablynx NV - Partnered Products in Pipeline, 2016
  • Ablynx NV - Out-Licensed Products in Pipeline, 2016
  • Ablynx NV - Pipeline by Target, 2016
  • Ablynx NV - Pipeline by Route of Administration, 2016
  • Ablynx NV - Pipeline by Molecule Type, 2016
  • Ablynx NV - Pipeline Products by Mechanism of Action, 2016
Back to Top